Jake Gaffey

Jan 15, 2025 | medcitynews.com | Peter Bonis |Jim Weinstein |Jake Gaffey |Eve McDavid

Earlier this summer, the landmark decision by The Supreme Court overruling the Chevron deference generated ripple effects across industries. The decision significantly impacts the latitude and autonomy federal agencies have had to define, interpret, and enforce regulations. In healthcare, the milestone serves as an opportunity to take stock of what has been accomplished so far with big data and what prospects look like ahead in this new regulatory landscape.

Jan 14, 2025 | medcitynews.com | Katie Adams |Jake Gaffey

We are only two weeks into 2025, and a small handful of healthcare AI companies have already announced funding rounds exceeding $100 million — signaling a strong start to what investors predicted would be another hot year for AI in the healthcare world. Last week, Innovaccer closed a $275 million round, and Hippocratic AI completed a $141 million round. This week, patient flow automation startup Qventus joined the fun.

Jan 14, 2025 | medcitynews.com | Marissa Plescia |Michael Blackman |Jake Gaffey

Solera Health, a healthcare technology company, has raised $40 million in Series E financing to expand access to digital health support, the company announced on Tuesday. In addition, Interim CEO John Santelli will officially assume the role of CEO. Phoenix, Arizona-based Solera Health is a digital health company that works with payers and employers to help match members and employees to point solutions.

Jan 14, 2025 | medcitynews.com | Nicola Wodlinger |Jake Gaffey

Health care solution developers design products that make health care organizations efficient and improve patient outcomes – after all, their goal is to make the road to relief as short and easy as possible. However, making a great tool is only one piece of the puzzle. Positive patient outcomes rely on patient compliance, the degree to which patients actually do what their health care practitioners asked them to do.

Jan 13, 2025 | medcitynews.com | Frank Vinluan |Michael Blackman |Jake Gaffey

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire Intra-Cellular Therapies, a company whose main asset has the potential to become a blockbuster seller across several neurological indications. According to deal terms announced Monday, J&J has agreed to pay $132 in cash for each share of Intra-Cellular, a more than 39% premium to the company’s closing stock price on Friday.